BioSpace News Archive

Deals

Recipharm AB publishes its report for the fourth quarter and full year 2018

Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom

February 21, 2019

·

6 min read

Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients

February 21, 2019

·

6 min read

Policy

AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.

February 21, 2019

·

5 min read

Business

Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production

Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.

February 21, 2019

·

3 min read

Deals

Firmly on our way to becoming a fully integrated biopharma company

FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability

February 21, 2019

·

12 min read

Business

Morphic and Janssen to Collaborate in Deal Worth up to $750 Million

Waltham, Mass.-based Morphic Therapeutic and Janssen Biotech, a division of Johnson & Johnson, entered into a collaborative deal to develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies.

February 21, 2019

·

2 min read

·

Alex Keown

Deals

IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American

India Globalization Capital, Inc. announced that it has successfully challenged NYSE American’s decision to delist the common stock of the Company from trading on the Exchange under the Exchange’s appeal procedures.

February 21, 2019

·

2 min read

Business

BioMarin Announces Full Year and Fourth Quarter 2018 Results

Global Phase 3 Vosoritide Study in Children with Achondroplasia Enrollment Complete with Data Expected by Year-end 2019

February 21, 2019

·

25 min read

Deals

Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.

February 21, 2019

·

2 min read

Business

Anika Reports Fourth Quarter and Full Year 2018 Financial Results

Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018

February 21, 2019

·

14 min read